Diabetes mellitus and stroke

International Journal of Clinical Practice

Volumn 60, Issue 1, 2006, Pages 48-56

  Idris, Iskandar ^a   Thomson, G A ^a   Sharma, J C ^a  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Carotid endarterectomy; Diabetes; Pathogenesis; Prevention; Stress hyperglycaemia; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPYRIDAMOLE; DIURETIC AGENT; ENALAPRIL; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; INDAPAMIDE; INSULIN; LOSARTAN; METFORMIN; PIOGLITAZONE; PRAVASTATIN; PROTEIN KINASE C; RAMIPRIL; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG; VALSARTAN; WARFARIN;

BEHAVIOR CHANGE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; COMORBIDITY; DIABETIC MICROANGIOPATHY; DISEASE COURSE; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; STROKE; TREATMENT OUTCOME; WEIGHT REDUCTION; CEREBROVASCULAR ACCIDENT; DIABETIC ANGIOPATHY; HYPERGLYCEMIA; METHODOLOGY;

ANTICOAGULANTS; CAROTID STENOSIS; CEREBROVASCULAR ACCIDENT; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; ENDARTERECTOMY, CAROTID; HUMANS; HYPERGLYCEMIA; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SMOKING CESSATION; WARFARIN;

EID: 33644834364     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00682.x     Document Type: Review

References (87)

1. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995; 30: 736-43.
2. Kissela BM, Khoury J, Kleindorfer D et al. Epidemiology of ischaemic stroke in patients with diabetes: The greater Cincinnati/northern Kentucky Stroke Study. Diabetes Care 2005; 28: 355-9.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
4. Folsom AR, Rasmussen ML, Chambless ME et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischaemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study investigators. Diabetes Care 1999; 22: 1077-83.
5. Hankey GJ, Jamrozik K, Broadhurst RJ et al. Long term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998; 29: 2491-500.
6. Tuomilehto J, Rastenyte D, Jousilahti P et al. Diabetes as a risk factor for death from stroke. Stroke 1996; 27: 210-5.
7. Megherbi S-A, Milan C, Minier D et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke. Data from the European BIOMED Stroke Project. Stroke 2003; 344: 688-94.
8. Sprafka JM, Virnig BA, Shahar E, McGovern PG. Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: The Minnesota Heart Survey. Diabet Med 1994; 11: 678-84.
9. Olsson T, Vitanen M, Asplund K et al. Prognosis after stroke in diabetic patients. A controlled prospective study. Diabetologia 1990; 33: 244-9.
10. Stevens RJ, Coleman RL, Adler A et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. UKPDS 66. Diabetes Care 2004; 27: 201-7.
11. Luchsinger JA, Tang MX, Stern Y et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in multiethnic cohort. Am J Epidemiol 2001; 154: 635-41.
12. You RX, McNeil JJ, O'Malley HM et al. Risk factors for stroke due to cerebral infarction in young adults. Stroke 1997; 28: 1913-8.
13. Rohr J, Kittner S, Feeser B et al. Traditional risk factors and ischaemic stroke in young adults. Arch Neurol 1996; 53: 603-7.
14. Lithner F, Asplund K, Eriksson S et al. Clinical characteristics in diabetic stroke patients. Diabetes Metab 1988; 4: 15-9.
15. Arauz A, Murillo L, Cantu C et al. Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging. Risk factors, recurrence and outcome in 175 consecutive cases. Stroke 2003; 34: 2453-8.
16. Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke 2003; 34: 392-6.
17. Mankovsky BN, Patrick JT, Metzger BE, Saver JL. The size of subcorticol ischaemic infarction in patients with and without diabetes mellitus. Clin Neurol Neurosurg 1996; 98: 137-41.
18. Toni D, De Michele M, Fiorelli M et al. Influence of hyperglycaemia on infarct size and clinical outcome of acute ischaemic stroke in patients with intracranial arterial occlusion. J Neurol Sci 1994; 123: 129-33.
19. Iwase M, Yamamoto M, Yoshinari M et al. Stroke topography in diabetic and nondiabetic patients by magnetic resonance imaging. Diabetes Res Clin Pract 1998; 42: 109-16.
20. Johnston CS, Sidney S, Bernstein AL, Gress DR. A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA. Neurology 2003; 28: 280-5.
21. Sacco RL, Benson RT, Kargman DE et al. High-density lipoprotein cholesterol and ischaemic stroke in the elderly. The North Manhattan Stroke Study. JAMA 2001; 285: 2729-35.
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
23. Fuller JH, Shipley MJ, Rose G et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study. Br Med J 1983; 287: 867-70.
24. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
25. Petitti DB, Bhatt H. Retinopathy as a risk factor for nonembolic stroke in diabetic subjects. Stroke 1995 2001; 26: 593-6.
26. Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischaemic stroke in non-insulin dependent diabetes mellitus. Stroke 1999; 30: 1787-91.
27. Toyry JP, Niskanen LK, Lansimies EA et al. Autonomic neuropathy predicts the development of stroke in patients with non-insulin dependent diabetes mellitus. Stroke 1996; 27: 1316-8.
28. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
29. Schmidt A, Yan S, Wautier J, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.
30. Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001; 44: 659-73.
31. Hennes MM, O'Shaughnessy IM, Kelly TM, LaBelle P, Egan BM, Kissebah AH. Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Hypertension 1996; 28: 120-6.
32. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
33. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications. Diabetes Metab Res Rev 2001; 17: 189-212.
34. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC-β inhibitor. Science 1996; 272: 728-31.
35. Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2003; 2: CD000029.
36. Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2004; 3: CD000024.
37. Albert GW, Clark WM, Madden KP, Hamilton SA. Atlantis trial: Results for patients treated within 3 hours of stroke onset. Alteplase thrombolysis for acute noninterventional therapy ischaemic stroke. Stroke 2002; 33: 493-5.
38. Alvarez-Sabin J, Molina CA, Ribo M et al. Impact of admission hyperglycaemia on stroke outcome after thrombolysis: Risk stratification in relation to time to perfusion. Stroke 2004; 35: 2493-8.
39. Capes SE, Hunt D, Malmberg K et al. Stress hyperglycaemia and prognosis of stroke on nondiabetic and diabetic patients. A systemic overview. Stroke 2001; 32: 2426-32.
40. Gray CS, Scott JF, French JM, Alberti KG, O'Connell JE. Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 2004; 33: 71-7.
41. Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
42. Van de Bergh G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-67.
43. Mallet RT, Hartman DA, Bunger R. Glucose requirement for post ischaemic recovery of perfused working heart. Eur J Biochem 1990; 188: 481-93.
44. Scott JF, Robinson GM, French JM. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycaemia. The Glucose Insulin Stroke Trial (GIST). Stroke 1999; 30: 793-9.
45. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S72-3.
46. Evangelista V, Totani L, Rotondo S et al. Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin. Thromb Haemost 2005; 93: 8-16.
47. Sacco M, Pellegrini F, Roncaglioni MC et al. Primary prevention of cardiovascular events with low dose aspirin and vitamin E in type 2 diabetes patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-72.
48. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
49. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: Lessons from the CAPRIE and CURE studies. Arch Intern Med 2004; 164: 2106-10.
50. Silvenius J, Laakso M, Piekkinen P Sr et al. European stroke prevention study: Effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke. Stroke 1992; 23: 851-4.
51. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ 2002; 325: 1022-5.
52. MacMahon S, Peto R, Cutler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
53. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-12.
54. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
55. Mallion JM, Baguet JP, Siche JP et al. Clinical value of ambulatory blood pressure monitoring. J Hypertens 1999; 17: 585-95.
56. Bella JN, Devereux RB, Roman MJ et al. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol 2001; 87: 1260-5.
57. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: Population based cohort study. BMJ 2003; 326: 681-4.
58. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
59. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 1004-10.
60. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-31.
61. Marre M, Puig JC, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR study. J Hypertens 2004; 22: 1613-22.
62. Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes: Results of the HOPE study and the MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
63. Svensson P, de Faire U, Sleight P et al. Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE substudy. Hypertension 2001; 38: E28-32.
64. Cruickshank JM. Beta-blockers and diabetes: The bad guys come good. Cardiovasc Drugs Ther 2002; 16: 457-470.
65. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
66. Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: How to combine drugs. J Hum Hypertens 2003; 17: 81-6.
67. Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
68. Keech A, Colquhoun D, Best J et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: Results from the LIPID trial. Diabetes Care 2003; 26: 2713-21.
69. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
70. Pederson TR, Kjekshus J, Pyorala K et al. Effect of simvastatin on ischaemic signs and symptoms in the Scandinavian simvastatin survival (4S) study. Am J Cardiol 1998; 81: 333-5.
71. Robins SJ, Collins D, Wittes JT et al VA-HIT Study Group. Veterans Affairs high-density lipoprotein intervention trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA 2001; 285: 1585-91.
72. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-420.
73. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
74. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971; 218: 1400-10.
75. Weih M, Amberger N, Wegener S et al. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 2001; 32: 2029-32.
76. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen study. Stroke 1998; 29: 1860-6.
77. Folsom AR, Prineas RJ, Kaye SA, Munger RG. Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. Stroke 1990; 21: 701-6.
78. Matsumoto K, Miyake S, Yano M et al. Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke. Diabetes Care 1999; 22: 1191-5.
79. Kernan WN, Inzucchi SE, Viscoli CM et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003; 34: 1431-1436
80. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004; 10: 2779-86.
81. Charbonnel B, Dormandy J, Erdmann E et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-53.
82. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-8.
83. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-53.
84. Ahari A, Bergqvist D, Troeng T et al. Diabetes mellitus as a risk factor for early outcome after carotid endarterectomy - a population-based study. Eur J Vasc Endovasc Surg 1999; 18: 122-6.
85. Ballotta E, Da Giau G, Renon L. Is diabetes mellitus a risk factor for carotid endarterectomy? A prospective study. Surgery 2001; 129: 146-52.
86. Pistolese GR, Appolloni A, Ronchey S, Martelli E. Carotid endarterectomy in diabetic patients. J Vasc Surg 2001; 33: 148-54.
87. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: An update. Health Education Authority. Thorax 2000; 55: 987-99.